Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph V Newman

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Antimicrobial Agents and Chemotherapy|December 30, 2010
Novel bacterial NAD+-dependent DNA ligase inhibitors with broad-spectrum activity and antibacterial efficacy in vivoScott D Mills, Ann E Eakin, Ed T Buurman, et al.
Antimicrobial Agents and Chemotherapy|August 9, 2017
The Fluorocycline TP-271 Is Efficacious in Models of Aerosolized Bacillus anthracis Infection in BALB/c Mice and Cynomolgus MacaquesTrudy H Grossman, Michael S Anderson, Lindsay Drabek, et al.
Journal of Medicinal Chemistry|May 16, 2014
Antibacterial inhibitors of Gram-positive thymidylate kinase: structure-activity relationships and chiral preference of a new hydrophobic binding regionSameer P Kawatkar, Thomas A Keating, Nelson B Olivier, et al.
Journal of Medicinal Chemistry|July 12, 2012
Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II with reduced pK(a): antibacterial agents with an improved safety profileFolkert Reck, Richard A Alm, Patrick Brassil, et al.
Nature Communications|March 14, 2025
Programmable mRNA therapeutics for controlled epigenomic modulation of single and multiplexed gene expression in diverse diseasesCharles W O'Donnell, Jeremiah D Farelli, Houda Belaghzal, et al.
Scientific Reports|September 19, 2015
Corrigendum: Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerasesGregory S Basarab, Gunther H Kern, John McNulty, et al.
Scientific Reports|July 15, 2015
Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerasesGregory S Basarab, Gunther H Kern, John McNulty, et al.
Bioorganic & Medicinal Chemistry|August 27, 2014
Optimization of physicochemical properties and safety profile of novel bacterial topoisomerase type II inhibitors (NBTIs) with activity against Pseudomonas aeruginosaFolkert Reck, David E Ehmann, Thomas J Dougherty, et al.
ACS Chemical Biology|August 23, 2012
In vivo validation of thymidylate kinase (TMK) with a rationally designed, selective antibacterial compoundThomas A Keating, Joseph V Newman, Nelson B Olivier, et al.
Journal of Medicinal Chemistry|October 10, 2012
Discovery of selective and potent inhibitors of gram-positive bacterial thymidylate kinase (TMK)Gabriel Martínez-Botella, John N Breen, James E S Duffy, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Antimicrobial Agents and Chemotherapy|December 30, 2010
Novel bacterial NAD+-dependent DNA ligase inhibitors with broad-spectrum activity and antibacterial efficacy in vivoScott D Mills, Ann E Eakin, Ed T Buurman, et al.
Antimicrobial Agents and Chemotherapy|August 9, 2017
The Fluorocycline TP-271 Is Efficacious in Models of Aerosolized Bacillus anthracis Infection in BALB/c Mice and Cynomolgus MacaquesTrudy H Grossman, Michael S Anderson, Lindsay Drabek, et al.
Journal of Medicinal Chemistry|May 16, 2014
Antibacterial inhibitors of Gram-positive thymidylate kinase: structure-activity relationships and chiral preference of a new hydrophobic binding regionSameer P Kawatkar, Thomas A Keating, Nelson B Olivier, et al.
Journal of Medicinal Chemistry|July 12, 2012
Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II with reduced pK(a): antibacterial agents with an improved safety profileFolkert Reck, Richard A Alm, Patrick Brassil, et al.
Nature Communications|March 14, 2025
Programmable mRNA therapeutics for controlled epigenomic modulation of single and multiplexed gene expression in diverse diseasesCharles W O'Donnell, Jeremiah D Farelli, Houda Belaghzal, et al.
Scientific Reports|September 19, 2015
Corrigendum: Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerasesGregory S Basarab, Gunther H Kern, John McNulty, et al.
Scientific Reports|July 15, 2015
Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerasesGregory S Basarab, Gunther H Kern, John McNulty, et al.
Bioorganic & Medicinal Chemistry|August 27, 2014
Optimization of physicochemical properties and safety profile of novel bacterial topoisomerase type II inhibitors (NBTIs) with activity against Pseudomonas aeruginosaFolkert Reck, David E Ehmann, Thomas J Dougherty, et al.
ACS Chemical Biology|August 23, 2012
In vivo validation of thymidylate kinase (TMK) with a rationally designed, selective antibacterial compoundThomas A Keating, Joseph V Newman, Nelson B Olivier, et al.
Journal of Medicinal Chemistry|October 10, 2012
Discovery of selective and potent inhibitors of gram-positive bacterial thymidylate kinase (TMK)Gabriel Martínez-Botella, John N Breen, James E S Duffy, et al.
Pageof 3